• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

L1210细胞系中铂化合物与1,2 - 二氨基环己烷载体配体的细胞内生物转化

Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line.

作者信息

Mauldin S K, Gibbons G, Wyrick S D, Chaney S G

机构信息

Department of Biochemistry and Nutrition, School of Medicine, University of North Carolina, Chapel Hill 27599.

出版信息

Cancer Res. 1988 Sep 15;48(18):5136-44.

PMID:3409241
Abstract

We have previously reported the development of a two-column high performance liquid chromatography system for separation of platinum(II) complexes with the 1,2-diaminocyclohexane (DACH) carrier ligand (Mauldin et al., Anal. Biochem., 157: 129, 1986). Here we report the application of this technique to the study of the intracellular biotransformations of (DL)-trans-1,2-diaminocyclohexanemalonatoplatinum(II) [PtCl2(trans-DACH)] and (DL)-trans-1,2-diaminocyclohexanemalonatoplatinum(II) [Pt(mal)(trans-DACH)] in the L1210 cell line. The two-column high performance liquid chromatography system allowed separation and identification of both parent drugs and intracellular biotransformation products containing glutathione, methionine, cysteine, arginine, lysine, aspartate or glutamate, and serine or threonine. With the exception of the platinum-glutathione complex, the relative abundance of each biotransformation product was independent of drug concentration. The relative abundance of the platinum-glutathione biotransformation product increased with increasing platinum concentration, suggesting that platinum drugs cause an increase in intracellular glutathione levels in a dose-dependent manner. This hypothesis was verified by direct measurement of intracellular glutathione levels. In continuous uptake experiments, the intracellular levels of the parent compounds peaked between 2 and 5 h and declined to negligible levels by 24 h. In pulse-chase experiments, the chemical t1/2 for PtCl2(trans-DACH) and Pt(mal)(trans-DACH) inside the cell at 37 degrees C was determined to be 12-15 and 21-28 min, respectively. This is far shorter than previously determined rates for the displacement of either ligand in vitro. The platinum-amino acid complexes accumulated gradually throughout the 24-h incubation. The free trans-DACH carrier ligand also accumulated to a level approaching 20% of filterable counts during the 24-h incubation, probably due to trans-labilization of the carrier ligand by sulfur-containing nucleophiles. A combination of reverse phase high performance liquid chromatography and a DNA binding assay was used to identify and quantitate the reactive biotransformation products. As expected from previous studies (Mauldin et al., Cancer Res., 46: 2876, 1986), the PtCl2(trans-DACH)-treated cells had approximately 3 times more reactive platinum biotransformation product at early times, but the levels of reactive biotransformation product fell much more rapidly than in Pt(mal)(trans-DACH)-treated cells. In the PtCl2(trans-DACH)-treated cells, the major reactive biotransformation product was the aquachloro species at all time points tested. In Pt(mal)(trans-DACH)-treated

摘要

我们之前报道了一种用于分离铂(II)与1,2 - 二氨基环己烷(DACH)载体配体形成的配合物的两柱高效液相色谱系统(莫尔丁等人,《分析生物化学》,157: 129, 1986)。在此,我们报告该技术在研究L1210细胞系中(DL)-反式 - 1,2 - 二氨基环己烷丙二酸铂(II)[PtCl2(反式 - DACH)]和(DL)-反式 - 1,2 - 二氨基环己烷丙二酸铂(II)[Pt(mal)(反式 - DACH)]细胞内生物转化方面的应用。该两柱高效液相色谱系统能够分离和鉴定母体药物以及含有谷胱甘肽、甲硫氨酸、半胱氨酸、精氨酸、赖氨酸、天冬氨酸或谷氨酸,还有丝氨酸或苏氨酸的细胞内生物转化产物。除了铂 - 谷胱甘肽配合物外,每种生物转化产物的相对丰度与药物浓度无关。铂 - 谷胱甘肽生物转化产物的相对丰度随铂浓度增加而增加,这表明铂药物以剂量依赖方式导致细胞内谷胱甘肽水平升高。这一假设通过直接测量细胞内谷胱甘肽水平得到了验证。在连续摄取实验中,母体化合物的细胞内水平在2至5小时达到峰值,并在24小时时降至可忽略不计的水平。在脉冲追踪实验中,37摄氏度时细胞内PtCl2(反式 - DACH)和Pt(mal)(反式 - DACH)的化学半衰期分别确定为12 - 15分钟和21 - 28分钟。这远比之前在体外测定的任何一种配体置换速率要短。铂 - 氨基酸配合物在整个24小时孵育过程中逐渐积累。游离的反式 - DACH载体配体在24小时孵育期间也积累到接近可过滤计数20%的水平,这可能是由于含硫亲核试剂使载体配体发生反式不稳定化所致。采用反相高效液相色谱和DNA结合测定相结合的方法来鉴定和定量反应性生物转化产物。正如之前研究(莫尔丁等人,《癌症研究》,46: 2876, 1986)所预期的那样,在早期,用PtCl2(反式 - DACH)处理的细胞中反应性铂生物转化产物大约多3倍,但反应性生物转化产物的水平下降速度比用Pt(mal)(反式 - DACH)处理的细胞快得多。在用PtCl2(反式 - DACH)处理的细胞中,在所有测试时间点,主要的反应性生物转化产物都是水合氯物种。在用Pt(mal)(反式 - DACH)处理的细胞中……

相似文献

1
Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line.L1210细胞系中铂化合物与1,2 - 二氨基环己烷载体配体的细胞内生物转化
Cancer Res. 1988 Sep 15;48(18):5136-44.
2
Effects of the bidentate malonate ligand on the utilization and cytotoxicity of platinum compounds in the L1210 cell line.双齿丙二酸酯配体对L1210细胞系中铂化合物利用及细胞毒性的影响。
Cancer Res. 1986 Jun;46(6):2876-82.
3
An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line.四氯-(d,l-反式)-1,2-二氨基环己烷铂(IV)(四铂)在L1210细胞系中的一条意外生物转化途径。
Cancer Res. 1991 Feb 1;51(3):969-73.
4
In vitro biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma.
Cancer Res. 1990 Aug 1;50(15):4539-45.
5
Role of carrier ligand in platinum resistance in L1210 cells.载体配体在L1210细胞铂耐药中的作用。
Cancer Res. 1990 Oct 15;50(20):6497-501.
6
Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.轴向和赤道配体对反式-1R,2R-二氨基环己烷铂(IV)配合物抗肿瘤活性的调节作用。
Anticancer Drug Des. 1994 Apr;9(2):139-51.
7
Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).轴向配体和脂环大小调节氨/环烷基胺-铂(IV)配合物在对顺二氯二氨铂(II)或反式-1R,2R-1S,2S-二氨基环己烷四氯铂(IV)耐药的肿瘤细胞中的活性和生化药理学。
Cancer Res. 1994 Sep 1;54(17):4691-7.
8
Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.轴向和赤道配体介导的1,2-二氨基环己烷铂(IV)配合物的细胞毒性和细胞药理学调节
Cancer Res. 1993 Oct 1;53(19):4567-72.
9
The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review).含1,2 - 二氨基环己烷载体配体的铂配合物的化学与生物学(综述)
Int J Oncol. 1995 Jun;6(6):1291-305. doi: 10.3892/ijo.6.6.1291.
10
Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.铂(II)辅助的铂(IV)取代对铂(IV)配合物氧化鸟苷衍生物的重要性。
Inorg Chem. 2008 Feb 18;47(4):1352-60. doi: 10.1021/ic701868b. Epub 2008 Jan 26.

引用本文的文献

1
Biological relevance of interaction of platinum drugs with -donor ligands.铂类药物与给体配体相互作用的生物学相关性。
Inorganica Chim Acta. 2019 Sep 1;495. doi: 10.1016/j.ica.2019.118974. Epub 2019 Jun 21.
2
Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.通过膀胱癌细胞培养模型中的功能和基因表达分析对诱导性铂耐药进行分子剖析
PLoS One. 2016 Jan 22;11(1):e0146256. doi: 10.1371/journal.pone.0146256. eCollection 2016.
3
Oxaliplatin and its enantiomer induce different condensation dynamics of single DNA molecules.
奥沙利铂及其对映体诱导单链 DNA 分子不同的凝聚动力学。
PLoS One. 2013 Aug 12;8(8):e71556. doi: 10.1371/journal.pone.0071556. eCollection 2013.
4
Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells.德博 0507 主要在 HCT116 细胞中形成二胺环戊烷-Pt-d(GpG)和-d(ApG)DNA 加合物。
Cancer Chemother Pharmacol. 2012 Mar;69(3):665-77. doi: 10.1007/s00280-011-1744-3. Epub 2011 Oct 4.
5
Oxaliplatin: pharmacokinetics and chronopharmacological aspects.奥沙利铂:药代动力学与时辰药理学方面
Clin Pharmacokinet. 2000 Jan;38(1):1-21. doi: 10.2165/00003088-200038010-00001.
6
Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin.与奥马铂和奥沙利铂相关的二氨基环己烷铂对映体的立体选择性外周感觉神经毒性。
Br J Cancer. 1997;76(4):502-10. doi: 10.1038/bjc.1997.416.
7
The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).非小细胞肺癌细胞系(PC-14)及其顺铂耐药亚系(PC-14/CDDP)中铂衍生物细胞摄取差异的机制。
Jpn J Cancer Res. 1993 Jan;84(1):83-92. doi: 10.1111/j.1349-7006.1993.tb02788.x.
8
Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial.奥马铂的药代动力学和生物转化研究以及一项I期临床试验
Cancer Chemother Pharmacol. 1994;33(4):347-54. doi: 10.1007/BF00685911.
9
Chemical stability, biological activity and cellular uptake of a cisplatin analogue having a 1,2-diarylethyleneamine ligand in cultures of human breast cancer cells.在人乳腺癌细胞培养物中,具有1,2 - 二芳基乙胺配体的顺铂类似物的化学稳定性、生物活性及细胞摄取情况
J Cancer Res Clin Oncol. 1995;121(1):31-8. doi: 10.1007/BF01202726.
10
New cisplatin analogues in development. A review.正在研发的新型顺铂类似物。一篇综述。
Drugs. 1993 Sep;46(3):360-377. doi: 10.2165/00003495-199346030-00003.